IMMUNOPRECISE ANTIBODIES LTD., a leader in full-service, therapeutic antibody discovery, announced that its board of directors has approved the grant of 25,000 stock options under its stock option plan to acquire up to an aggregate of 25,000 common shares in the capital of IPA.
January 6, 2021
· 3 min read